The research will ultimately benefit millions of sufferers of sleep-disordered breathing worldwide.
Under the agreement, ResMed Limited will pay $25million to the University to support its work, including the establishment of two perpetual academic chairs.
The agreement also provides for the settlement of proceedings between the parties in the Australian Federal Court regarding a dispute over an earlier licensing agreement.
“Sleep-disordered breathing is a global health problem affecting one in five adults, with broad and deep implications in other chronic conditions, such as hypertension and heart failure,” said ResMed CEO, Michael Farrell.
“With this partnership, we look forward to the University’s research revealing new information on how to battle this costly and life-threatening condition.”
ResMed is an innovator in developing products for treating sleep-disordered breathing and respiratory conditions.
The company’s Norwest office is headquarters for its Asia-Pacific operations and it employs more than 1,200 people.
University of Sydney, Vice-Chancellor, Dr Michael Spence said the agreement “would allow the University to further develop its path-finding research in these critically important areas, as well as provide future opportunities for our researchers.”
